The Ward Study for SeptiCyte® Lab to Distinguish Between Infection-positive and Infection-negative SIRS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

66 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-06-30

Study Completion Date

2018-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A non-interventional, prospective observational study to assess the performance of SeptiCyte® Lab to diagnose patients identified as suspected of sepsis in general medical and surgical wards with infection-positive from infection-negative SIRS

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Near Patient Molecular Testing in Sepsis

NCT05469048

Sepsis Systemic Inflammatory Response Syndrome

COMPLETED

Molecular Early Sepsis Identification Study

NCT05833412

Sepsis Molecular Diagnosis

UNKNOWN

VENUS: Septic Gene Expression Using SeptiCyte

NCT02127502

Sepsis Systemic Inflammatory Response Syndrome (SIRS)

COMPLETED

A Blood Test to Diagnose Sepsis in Symptomatic Adults and Children

NCT05142813

Infections Sepsis SIRS

UNKNOWN

Nasal and Gut Microbiota Combined Clinical Events Predicts the Prognosis of Septic Patients

NCT05143736

Sepsis Septic Shock

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is evaluating a molecular diagnostic device developed to distinguish between sepsis and infection-negative SIRS among critically ill patients.

This study is a prospective, non-randomized, non-interventional, observational trial of patients with suspected sepsis in the medical and/or surgical wards. The study is being conducted on two preselected patient care units.

All patients identified by a local screening tool undergo physician review. If the suspicion of sepsis is found to be plausible, routine and conventional diagnostic procedures, including: routine bloods, blood culture and specialized tests are conducted.

Blood collection for SeptiCyte® Lab and SeptID® is drawn within 6 hours of a positive screen - both use peripheral blood as the clinical sample. The diagnostic performance of the two experimental assays will be compared to Retrospective Physician Diagnosis (RPD), and conventional microbiological culture. The results of SeptiCyte® Lab and SeptID® are not used in any clinical decision-making.

This data will be used to analyze the performance of SeptiCyte® Lab according to the endpoint measures.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis SIRS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SeptiCyte Lab molecular diagnostic test (non-interventional)

This is not an interventional study. Rather it involves evaluation of a molecular diagnostic test to distinguish between sepsis and infection-negative SIRS based on host response.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 18-89 years old on the day of enrollment.
2. Currently admitted to study designated medical or surgical ward
3. Have a clinical suspicion of sepsis as determined by two physicians after identification by hospital screening tool.
4. Screened positive for sepsis, severe sepsis or septic shock using the RISE2 screening tool.
5. Completed SBAR handover (Situation, Background, Assessment, Recommendation)
6. SIRS present as defined by the presence of two or more of the following:

* Temperature \> 38°C or \< 36°C
* Heart Rate \> 90 beat/min
* Tachypnea \> 20/min or PaCO2 \< 32 mmHg
* WBC count \> 12 000/mm3 or \< 4 000/mm3 or \> 10% immature neutrophils (bands)

Exclusion Criteria

1. Consent not provided
2. Patients less than 18 years of age, or 90 years of age or older.
3. Patients for which a blood sample could not be taken within 24 hours of a physician first determining a clinical suspicion of sepsis.
4. Patients that are not located in the designated medical or surgical ward associated with the study.
5. Patients listed for "Comfort Measures Only".
6. Less than 2 SIRS criteria
7. Commencement of narrow spectrum directed antibiotics prior to screening.

Minimum Eligible Age

18 Years

Maximum Eligible Age

89 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No